CLINICAL HYPERTHERMIA--HYPERTHERMIA & RADIATION THERAPY FOR PROSTATE CANCER

该计划的主要重点是针对疾病部位的治疗。 局部晚期前列腺癌和膀胱癌是深层次肿瘤 本地故障率较高的站点。为了改善当地的环境 在这些部位控制肿瘤，我们将利用合并剂 高热(HT)和放射之间的影响。使用站点特定的 加热前列腺和膀胱的方法我们将检验这一假说 热和辐射的结合导致局部肿瘤的改善 这可能会增加患者的存活率。我们计划将其与 肿瘤和正常组织温度达到的临床结果和 与患者肿瘤活检取样器中的生物学参数进行测量。 临床研究的三个具体领域如下； 前列腺癌：我们正在结合一种特定部位的HT治疗方法 放射治疗(RT)治疗局部晚期肺癌 前列腺癌。标准时间内将交付两次超音速运输 使用先前开发的经直肠超声敷贴器进行放射治疗 已经被证明有能力加热前列腺。主端点 这项II期研究的毒性和有效性(以肿瘤衡量 回应)。生存和生活质量也将被评估。 深部肿瘤：我们将继续评估AAT的能力和 聚焦分段超声机(FSUM)的局限性 热疗系统联合放射治疗晚期肺癌的临床研究 使用临床方案的深层肿瘤正在进行中。我们还计划 评估FSUM提供的RT在合并时的潜在作用 外BEAM RT治疗内科不能手术或 晚期膀胱移行细胞癌。超音速快递将被交付 在RT过程中进行两次；可对膀胱进行警告冲洗 以提高HT的均质性。改善了这些地区的局部肿瘤控制 患者可能会导致更频繁的膀胱器官保留。 热疗调节剂：我们将确定其疗效和毒性 联合应用羟色胺、放射治疗和化学调节剂治疗一系列II期临床 旨在治疗局部持续性、复发性或间变性的试验 浅表肿瘤。第一个被测试的改性剂将是依坦硝唑； 第二项研究将评估替拉帕明。

The major focus of this program is on disease site-specific therapy. Locally advanced prostate cancer and bladder cancer are deep-seated tumor sites with high rates of local failure. In order to improve the local tumor control in these sites we will take advantage of the syergistic effect between hyperthermia (HT) and radiation. Using a site-specific approach to heat the prostate and the bladder we will test the hypothesis that the combination of heat and irradiation leads to improved local tumor control which may lead to increased patient survival. We plan to correlate clinical outcome with the tumor and normal tissue temperatures achieved and with biological parameters measured in biopsy sampler of patient's tumors. The three specific areas of clinical research are as follows; PROSTATE CANCER: We are combining a site-specific HT treatment method with radiation therapy (RT) to treat patients with locally advanced adenocarcinoma of the prostate. HT will be delivered twice during standard RT using a previously developed transrectal ultrasound applicator that has been shown capable of heating the prostate gland. The primary endpoints for this Phase II study are toxicity and efficacy (as measured by tumor response). Survival and quality of life will also be evaluated. DEEP TUMORS: We will continue to evaluate athe capabilities and limitations of athe focused segmented ultrasound machine (FSUM) hyperthermia system combined with radiation therapy to treat advanced and deep seated tumors using the clinical protocol in progress. We also plan to evaluate athe potential role of RT delivered by the FSUM when combined with external beam RT to treat patients with medically inoperable or advanced transitional cell carcinoma of the bladder. HT will be delivered twice during the course of RT; warn irrigation of the bladder is available to improve the homogeneity of HT. Improved local tumor control in these patients may lead to more frequent urinary bladder organ preservation. HYPERTHERMIA MODIFIERS: We will determine the efficacy and toxicity of combined HT, RT, and chemical modifiers in a series of Phase II clinical trials designed to treat locally persistent, recurrent, or metastic superficial tumors. The first modifier to be tested will be etanidazole; the second study will evaluate tirapazimine.